Search

Your search keyword '"Elsabah, Hesham"' showing total 28 results
Start Over Author "Elsabah, Hesham"
28 results on '"Elsabah, Hesham"'

3. Venetoclax in the treatment of secondary plasma cell leukemia with translocation t(11;14): a case report and literature review.

Author

Elsabah, Hesham, Ghasoub, Rola, El Omri, Halima, Benkhadra, Maria, Cherif, Honar, and Taha, Ruba Y.

Subjects
PLASMA cell leukemia, LITERATURE reviews, VENETOCLAX, IMMUNOGLOBULIN light chains, STEM cell transplantation, MONOCLONAL gammopathies
Abstract

Introduction: Venetoclax is a BCL-2 inhibitor with proven efficacy in patients with multiple myeloma (MM) and translocation t(11;14). However, its role in plasma cell leukemia (PCL) remains unclear. Herein, we aimed to report a case of relapsed MM with secondary PCL and t(11;14) achieving complete (CR) and durable remission with venetoclax therapy. Case presentation: A 52-year-old gentleman was diagnosed with MM-free light chain lambda (ISS III) in December 2016. He received induction therapy, followed by autologous stem cell transplant. (ASCT) in May 2017 and maintenance. A year later, the patient relapsed with secondary PCL. His cytogenetics analysis revealed t(11; 14). The patient failed salvage chemotherapy and was shifted to venetoclax with dexamethasone treatment. The patient attained complete remission (CR), which was maintained for two years and a half before he developed fatal COVID-19 pneumonia. Conclusion: In comparison with the reported literature, this case report offers the latest compilation of the available evidence on the use of venetoclax in patients with PCL. Furthermore, our patient achieved CR for the longest reported durable response in literature thus far. Prospective clinical trials are needed to elucidate the optimal dosage, combination, and duration of treatment, ensuring better representation and generalizability of the findings. Meanwhile, venetoclax may be considered as a therapeutic option in patients with PCL t(11;14). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Real world evidence of epidemiological trends, clinical presentation, and prognostic outcomes of multiple myeloma (2007-2021)

Author

Elsabah, Hesham, primary, El Omri, Halima, additional, Habas, Elmukhtar, additional, Taha, Ruba Y., additional, ElKourashy, Sarah A., additional, Ibrahim, Feryal, additional, Nashwan, Abdulqadir J., additional, Kassem, Nancy, additional, Ojha, Laxmi, additional, Singh, Rajvir, additional, Ghasoub, Rola, additional, and El Omri, Abdelfatteh, additional

Published
2024
Full Text
View/download PDF

8. Carfilzomib-induced life-threatening lung injury in refractory multiple myeloma.

Author

Ghasoub, Rola, Benkhadra, Maria, Kassem, Nancy, Alshurafa, Awni, and Elsabah, Hesham

Subjects
ANTIBIOTICS, LUNG injuries, ECHOCARDIOGRAPHY, PROTEASE inhibitors, CHEST X rays, ANTINEOPLASTIC agents, TREATMENT duration, TREATMENT effectiveness, MULTIPLE myeloma, HYDROCORTISONE
Abstract

Introduction: Carfilzomib is a second-generation selective proteasome inhibitor that is commonly used in the treatment of relapsed or refractory multiple myeloma. Carfilzomib is associated with respiratory side effects, such as cough, dyspnea, and upper respiratory tract infection. However, severe pulmonary toxicity is rare and is only reported in a few case reports. Case report: Here, we present a case of a 65-year-old male with refractory multiple myeloma who developed a life-threatening lung injury during his third cycle of carfilzomib. The patient presented with a decreased level of consciousness and was found to have Type I respiratory failure. He was admitted to the intensive care unit, where he was intubated. Blood cultures and viral panel were negative. The patient received a prolonged course of antibiotics with 2 days of hydrocortisone. Management and outcomes: After discharge, repeated myeloma workup showed disease progression and carfilzomib was reintroduced. The next day, he presented with fever, vomiting, and hypoxia. Chest x-ray showed congestive lung changes with patchy airspace opacities. Repeated echocardiography showed normal ejection fraction with moderate pulmonary hypertension (RVSP 46 mm Hg). The patient was transferred again to the ICU and kept on continuous positive airway pressure. Antibiotics were started, and blood cultures and respiratory viral panels were negative for any infectious organism. The patient improved in terms of inflammatory markers and oxygen requirements. Treatment with carfilzomib was stopped permanently. Discussion: Pulmonary toxicity associated with carfilzomib in patients with multiple myeloma can be potentially life-threatening. The mechanism with which carfilzomib induces lung-related AEs is still not fully understood. In our patient, carfilzomib-induced lung injury was evident after rechallenging the patient with carfilzomib, in the radiographic x-ray changes and the new onset moderate pulmonary hypertension. Healthcare providers should be encouraged to report rare adverse events in order to identify the risk factors that can predispose patients to the development of these adverse events. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

10. Characteristics and Outcomes of Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML): A Single Center Experience

Author

Mohamed, Shehab Fareed, primary, Afana, Mohammad, additional, Soliman, Dina Sameh, additional, Abbas, Feryal, additional, El Omri, Halima, additional, Abuasab, Tareq, additional, Haddad, Fadi, additional, Yassin, Mohamed A, additional, Mudawi, Deena Sideeg, additional, Elsabah, Hesham, additional, Kohla, Samah, additional, Amer, Aliaa, additional, Mulikandathil, Yahya, additional, Gameil, Amna, additional, Alshurafa, Awni, additional, Singh, Kalpana, additional, and Cherif, Honar, additional

Published
2022
Full Text
View/download PDF

11. A Comparative Study between Acute Myeloid Leukemia in Adolescent and Young Adults (AYA) Versus Non-AYA Patients: Single Center Experience

Author

Mohamed, Shehab Fareed, primary, Alshurafa, Awni, additional, Soliman, Dina Sameh, additional, El Omri, Halima, additional, Mudawi, Deena Sideeg, additional, Yassin, Mohamed A, additional, Afana, Mohammad, additional, Elsabah, Hesham, additional, Ellahie, Anil Yousaf, additional, Kassem, Nancy, additional, Abuasab, Tareq, additional, Haddad, Fadi, additional, Kohla, Samah, additional, Amer, Aliaa, additional, Singh, Kalpana, additional, and Cherif, Honar, additional

Published
2022
Full Text
View/download PDF

15. Characteristics and Outcomes of Adolescent, Young Adults, and Adults 40-50 Years Old with Multiple Myeloma: A Single Center Experience

Author

Mohamed, Shehab, Elsabah, Hesham, Shawayli, Hawra, Abbas, Feryal, Soliman, Dina Sameh, Afana, Mohammad, Mudawi, Deena, Kohla, Samah Ahmed Samy, El Omri, Halima, Kessam, Nancy, Ellahie, Anil, Abdulgayoom, Mohammed, Mulikandathil, Yahya, Ganow, Ibrahim, Alshurafa, Awni, Singh, Kalpana, Gameil, Amna, and Cherif, Honar

Published
2023
Full Text
View/download PDF

23. Acute Myeloid Leukemia in Qatar (2010–2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes

Author

El Omri, Halima, primary, Taha, Ruba Yasin, additional, Elomri, Adel, additional, Kacem, Nancy, additional, Elsabah, Hesham, additional, Ellahie, Anil Yousaf, additional, Gamil, Amna, additional, Ibrahim, Firyal, additional, Soliman, Dina Sameh Abdelrahman, additional, El Akiki, Susanna Jane Lawson, additional, Nawaz, Zafar, additional, Al Sabbagh, Ahmad, additional, and El Omri, Abdelfatteh, additional

Published
2020
Full Text
View/download PDF

24. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice

Author

Cerrano, Marco, primary, Ruella, Marco, additional, Perales, Miguel-Angel, additional, Vitale, Candida, additional, Faraci, Danilo Giuseppe, additional, Giaccone, Luisa, additional, Coscia, Marta, additional, Maloy, Molly, additional, Sanchez-Escamilla, Miriam, additional, Elsabah, Hesham, additional, Fadul, Afraa, additional, Maffini, Enrico, additional, Pittari, Gianfranco, additional, and Bruno, Benedetto, additional

Published
2020
Full Text
View/download PDF

26. Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling

Author

Akhtar, Sabah, primary, Achkar, Iman W., additional, Siveen, Kodappully S., additional, Kuttikrishnan, Shilpa, additional, Prabhu, Kirti S., additional, Khan, Abdul Q., additional, Ahmed, Eiman I., additional, Sahir, Fairooz, additional, Jerobin, Jayakumar, additional, Raza, Afsheen, additional, Merhi, Maysaloun, additional, Elsabah, Hesham M., additional, Taha, Ruba, additional, Omri, Halima El, additional, Zayed, Hatem, additional, Dermime, Said, additional, Steinhoff, Martin, additional, and Uddin, Shahab, additional

Published
2019
Full Text
View/download PDF

27. PB1952: CLL IN AYA.

Author

Mohamed, Shehab, Soliman, Dina, Taha, Ruba, Elsabah, Hesham, Alshurafa, Awni, Gamil, Amna, Yassin, Mohamed, and Ibrahim, Firyal

Published
2023
Full Text
View/download PDF

28. Relapsed IgA Multiple Myeloma as Testicular Plasmacytoma after Quadrable Novel Therapy and Autologous Stem Cell Transplant: A Rare Case Report and Literature Review.

Author

Abdulgayom M, Soliman D, Helmy A, Haroon A, Telfah H, Ghasoub R, Fareed S, and Elsabah H

Abstract

Introduction: Multiple myeloma (MM) is a clonal neoplasm of plasma cells that may manifest as an extramedullary disease in rare cases., Case Report: In this case report, we present the rare occurrence of testicular relapse in a 39-year-old patient with IgA MM after 3 years of remission. We discuss the clinical course and management of this unusual presentation and provide a comprehensive literature review of testicular involvement by MM., Conclusion: Despite advances in MM treatment, relapse remains common, highlighting the importance of careful follow-up and timely detection of disease recurrence at atypical sites. This case highlights the need for further research to standardize the diagnosis and treatment of testicular MM., Competing Interests: The authors have no conflicts of interest., (© 2024 The Author(s). Published by S. Karger AG, Basel.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results